Trastuzumab emtansine for HER2-positive advanced breast cancer. New england journal of medicine, October 2012.
Verma, S., et al.
http://www.nejm.org/doi/full/10.1056/NEJMoa1209124#t=articleTop
We randomly assigned patients with HER2-positive advanced breast cancer, who had previously been treated with trastuzumab and a taxane, to T-DM1 or lapatinib plus capecitabine. The primary end points were progression-free survival (as assessed by independent review), overall survival, and safety. Secondary end points included progression-free survival (investigator-assessed), the objective response rate, and the time to symptom progression. Two interim analyses of overall survival were conducted.
